Anixa Biosciences receives clearance to initiate clinical trial of breast cancer vaccine developed by Cleveland Clinic research

The U.S. Food and Drug Administration has cleared an Investigational New Drug application from Anixa Biosciences Inc. (Nasdaq: ANIX) for its breast cancer vaccine, which was invented by a Cleveland Clinic research term.

This breast cancer vaccine technology was invented and developed by Cleveland Clinic immunologist Dr. Vincent Tuohy, and his research team developed the technology. Dr. Thomas Budd, a Clinic oncologist, will lead the clinical trial, according to a news release.

Click here to read the complete story.

Story excerpt provided by Crain’s Cleveland Business.

Written by Lydia Coutré.

Originally published December 21, 2020.